Drug-induced hyperthermia with rhabdomyolysis in CLN3 disease

被引:4
|
作者
Savvidou, A. [1 ,2 ]
Jennions, E. [1 ,2 ]
Wikstrom, S. [3 ,4 ]
Olsson-Engman, M. [5 ]
Sofou, K. [1 ,2 ]
Darin, N. [1 ,2 ]
机构
[1] Univ Gothenburg, Inst Clin Sci, Sahlgrenska Acad, Dept Pediat, Gothenburg, Sweden
[2] Sahlgrens Univ Hosp, Dept Pediat, Reg Vastra Gotaland, Gothenburg, Sweden
[3] Cty Council Varmland, Ctr Clin Res & Educ, Varmland, Sweden
[4] Orebro Univ, Sch Med Sci, Orebro, Sweden
[5] Blekinge Hosp, Pediat Clin, Karlskrona, Sweden
关键词
Juvenile neuronal ceroid lipofuscinosis; CLN3; Neuroleptic malignant syndrome; Serotonin syndrome; Rhabdomyolysis; Neuroleptic malignant; NEUROLEPTIC MALIGNANT SYNDROME; SEROTONIN SYNDROME;
D O I
10.1016/j.ejpn.2022.06.007
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
CLN3 disease (MIM# 204200), the most prevalent of the neuronal ceroid lipofuscinoses (NCL), is an autosomal recessive disorder with juvenile onset characterized by blindness, epilepsy, dementia, psychiatric manifestations, and motor deterioration. Problems related to behavior, emotions and thought are among the main features. Antidepressant and antipsychotic drugs have been employed with variable results. Neuroleptic malignant syndrome (NMS) has previously been described in two patients with NCL, one with CLN3 disease and one with adult onset NCL of unclear genetic origin. Our aims were to describe the occurrence of drug-induced hyperthermia in pediatric patients with CLN3 disease from West and South Sweden and to delineate the range of associated clinical features. Our study identified four patients presenting with seven episodes of severe drug-induced hyperthermia and either NMS-like or Serotonin syndrome (SS)-like features. Possibly provoking drugs were risperidone, clozapine, olanzapine, haloperidol, quetiapine, and sertraline. The course was atypical, frequently prolonged, associated with rhabdomyolysis and status dystonicus, and resulted in the death of three of the patients. Our study points to a vulnerability to drug-induced hyperthermia in patients with CLN3 disease which we believe could be underreported. Interestingly the proposed pathophysiological mechanisms behind NMS and SS on one hand and CLN3 on the other hand seem to converge in a common mechanism involving dysregulation of the sympathetic nervous system.
引用
收藏
页码:74 / 78
页数:5
相关论文
共 50 条
  • [21] Drug-Induced Hyperthermia Review
    Horseman, Michael
    Panahi, Ladan
    Udeani, George
    Tenpas, Andrew S.
    Verduzco, Rene, Jr.
    Patel, Pooja H.
    Bazan, Daniela Z.
    Mora, Andrea
    Samuel, Nephy
    Mingle, Anne-Cecile
    Leon, Lisa R.
    Varon, Joseph
    Surani, Salim
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [22] Nature of Batten disease CLN3 protein in brain
    Pullarkat, RK
    Pullarkat, PS
    Morris, GN
    JOURNAL OF NEUROCHEMISTRY, 1997, 69 : S193 - S193
  • [23] Mutations in CLN3 gene responsible of Batten disease
    Milà, M
    Mallolas, J
    Pineda, M
    Ferrer, I
    Vernet, A
    Badenas, C
    Sánchez, A
    Ballesta, F
    EUROPEAN JOURNAL OF HUMAN GENETICS, 1998, 6 : 145 - 145
  • [24] Management of drug-induced hyperthermia
    Halloran, LL
    Bernard, DW
    CURRENT OPINION IN PEDIATRICS, 2004, 16 (02) : 211 - 215
  • [25] Spectrum of mutations in the Batten disease gene, CLN3
    Munroe, PB
    Mitchison, HM
    ORawe, AM
    Anderson, JW
    Boustany, RM
    Lerner, TJ
    Taschner, PEM
    deVos, N
    Breuning, MH
    Gardiner, RM
    Mole, SE
    AMERICAN JOURNAL OF HUMAN GENETICS, 1997, 61 (02) : 310 - 316
  • [26] Exogenous Galactosylceramide as Potential Treatment for CLN3 Disease
    El-Sitt, Sally
    Soueid, Jihane
    Maalouf, Katia
    Makhoul, Nadine
    Al Ali, Jamal
    Makoukji, Joelle
    Asser, Bilal
    Daou, Daniel
    Harati, Hayat
    Boustany, Rose-Mary
    ANNALS OF NEUROLOGY, 2019, 86 (05) : 729 - 742
  • [27] Structure of the CLN3 gene and predicted structure, location and function of CLN3 protein
    Mitchison, HM
    Taschner, PEM
    Kremmidiotis, G
    Callen, DF
    Doggett, NA
    Lerner, TJ
    Janes, RB
    Wallace, BA
    Munroe, PB
    ORawe, AM
    Gardiner, RM
    Mole, SE
    NEUROPEDIATRICS, 1997, 28 (01) : 12 - 14
  • [28] DRUG-INDUCED AND TOXIN-INDUCED RHABDOMYOLYSIS
    CURRY, SC
    CHANG, D
    CONNOR, D
    ANNALS OF EMERGENCY MEDICINE, 1989, 18 (10) : 1068 - 1084
  • [29] SURGICAL IMPLICATIONS OF DRUG-INDUCED RHABDOMYOLYSIS
    RUTGERS, PH
    VANDERHARST, E
    KOUMANS, RKJ
    BRITISH JOURNAL OF SURGERY, 1991, 78 (04) : 490 - 492
  • [30] SURGICAL IMPLICATIONS OF DRUG-INDUCED RHABDOMYOLYSIS
    PAYNE, SPK
    LLOYD, DML
    BRITISH JOURNAL OF SURGERY, 1992, 79 (07) : 717 - 717